Endometrial Cancer clinical trials in West Virginia

6 actively recruiting endometrial cancer trials at 6 sites across West Virginia.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting NIH

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05256225

Sites in West Virginia:

West Virginia University Charleston Division — Charleston, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, …

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07198074

Sites in West Virginia:

United Hospital Center — Bridgeport, West Virginia
West Virginia University Charleston Division — Charleston, West Virginia
WVUH-Berkely Medical Center — Martinsburg, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia
Camden Clark Medical Center — Parkersburg, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…

Sponsor: AstraZeneca

NCT ID: NCT07044336

Sites in West Virginia:

Research Site — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in West Virginia:

West Virginia University Charleston Division — Charleston, West Virginia
Edwards Comprehensive Cancer Center — Huntington, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554328

Sites in West Virginia:

Edwards Comprehensive Cancer Center — Huntington, West Virginia
West Virginia University Healthcare — Morgantown, West Virginia

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in West Virginia:

Massive Bio SYNERGY-AI site — Morgantown, West Virginia

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20